{"id":8953,"date":"2021-04-12T10:36:56","date_gmt":"2021-04-12T17:36:56","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8953"},"modified":"2021-04-13T10:37:34","modified_gmt":"2021-04-13T17:37:34","slug":"evidence-for-increased-breakthrough-rates-of-sars-cov-2-variants-of-concern-in-bnt162b2-mrna-vaccinated-individuals","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/12\/evidence-for-increased-breakthrough-rates-of-sars-cov-2-variants-of-concern-in-bnt162b2-mrna-vaccinated-individuals\/","title":{"rendered":"Evidence for Increased Breakthrough Rates of SARS-CoV-2 Variants of Concern in BNT162b2 MRNA Vaccinated Individuals"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> A case-control study of individuals with SARS-CoV-2 infection in Israel who received the Pfizer vaccine (cases) versus unvaccinated carriers (controls) found that the predominant SARS-CoV-2 variant among vaccine recipients <\/span><span style=\"font-weight: 400\">with a positive SARS-CoV-2 PCR result <\/span><span style=\"font-weight: 400\">differed depending on their timing in the vaccine course. Compared to controls, vaccinated individuals infected <\/span><span style=\"font-weight: 400\">at least a week after the second dose were disproportionally infected with <\/span><span style=\"font-weight: 400\">the <\/span><span style=\"font-weight: 400\">B.1.351 <\/span><span style=\"font-weight: 400\">variant <\/span><span style=\"font-weight: 400\">(<\/span><span style=\"font-weight: 400\">OR=<\/span><span style=\"font-weight: 400\">8), <\/span><span style=\"font-weight: 400\">while those <\/span><span style=\"font-weight: 400\">infected between two weeks after the first dose and one week after the second dose were disproportionally infected by B.1.1.7 (odds ratio of 26:10)<\/span><span style=\"font-weight: 400\">. The B.1.351 variant was not evaluated at this time point due to low case numbers of B.1.351. The authors<\/span> <span style=\"font-weight: 400\">suggest there may be <\/span><span style=\"font-weight: 400\">reduced vaccine effectiveness against both variants of concern under different conditions of <\/span><span style=\"font-weight: 400\">number of<\/span><span style=\"font-weight: 400\"> dos<\/span><span style=\"font-weight: 400\">es and dose <\/span><span style=\"font-weight: 400\">timing. <\/span><span style=\"font-weight: 400\">T<\/span><span style=\"font-weight: 400\">he B.1.1.7 variant was found to be the predominant strain over the study period.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Kustin et al.\u00a0(Apr 9, 2021). Evidence for Increased Breakthrough Rates of SARS-CoV-2 Variants of Concern in BNT162b2 MRNA Vaccinated Individuals. Pre-print downloaded Apr 12 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.06.21254882\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.06.21254882<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] A case-control study of individuals with SARS-CoV-2 infection in Israel who received the Pfizer vaccine (cases) versus unvaccinated carriers (controls) found that the predominant SARS-CoV-2 variant among vaccine recipients with a positive SARS-CoV-2 PCR result differed depending on their timing in the vaccine course. Compared to controls, vaccinated individuals infected at least&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/12\/evidence-for-increased-breakthrough-rates-of-sars-cov-2-variants-of-concern-in-bnt162b2-mrna-vaccinated-individuals\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[142,141],"topic":[31],"class_list":["post-8953","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccine","tag-variant","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8953"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8953\/revisions"}],"predecessor-version":[{"id":8954,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8953\/revisions\/8954"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8953"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}